Thoratec Set To Begin U.S. Trial Of Catheter Heart Pump To Assist PCI
This article was originally published in The Gray Sheet
Executive Summary
FDA has conditionally approved a 425-patient trial, called SHIELD II, comparing Thoratec's HeartMate PHP to Abiomed's Impella 2.5. The company expects the study to begin in the third quarter.
You may also be interested in...
Thoratec Takes Steps Into PCI-Support Market With EU Roll-Out Of HeartMate PHP
The company plans a targeted roll-out of its heart pump in select European markets following a CE mark for the device, indicated to help stabilize patients during high-risk percutaneous coronary interventions.
Impella 2.5 PMA Gives Abiomed Big Growth Potential For High-Risk PCIs
The approval, the first for a percutaneous hemodynamic support device, frees Abiomed's hand to market the miniature blood pump to a relatively broad patient population, analysts note.
Thoratec Looks To Next-Generation LVADs To Revive Sinking Sales
Thoratec reported a near 10 percent year-over-year decline in revenue in the second quarter; physicians have become more selective about which patients to implant with a HeartMate II ventricular assist device, the firm says. The company is looking to next-generation of HeartMate products as well as the technology it acquired in the Apica deal to help it return to growth.